Top Page
Ascendis Pharma
(NASDAQ:ASND)
Ascendis Pharma (ASND) vs. SPDR S&P 500 ETF (SPY)
Ascendis Pharma Business Overview & Revenue Model
Ascendis Pharma Key Performance Indicators (KPIs)
Shows the income generated from products that have reached the market, indicating the company's ability to convert R&D efforts into profitable offerings and its success in capturing market share.
The FlyAscendis Pharma Earnings Call Summary
Ascendis Pharma Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 691.71M | 363.64M | 266.72M | 51.17M | 7.78M |
| Gross Profit | 588.53M | 319.38M | 222.32M | 39.04M | 4.25M |
| EBITDA | -113.90M | -290.02M | -411.17M | -529.18M | -364.64M |
| Net Income | -219.03M | -378.08M | -481.45M | -583.19M | -383.58M |
Balance Sheet | |||||
| Total Assets | 1.30B | 1.18B | 825.59M | 1.09B | 1.08B |
| Cash, Cash Equivalents and Short-Term Investments | 615.78M | 559.54M | 399.44M | 735.46M | 682.06M |
| Total Debt | 871.41M | 856.62M | 743.06M | 617.57M | 209.92M |
| Total Liabilities | 1.46B | 1.29B | 971.28M | 826.39M | 201.29M |
| Stockholders Equity | -162.75M | -105.71M | -145.70M | 263.35M | 883.63M |
Cash Flow | |||||
| Free Cash Flow | 43.62M | -307.62M | -469.80M | -510.19M | -441.88M |
| Operating Cash Flow | 51.77M | -306.20M | -467.36M | -495.70M | -417.65M |
| Investing Cash Flow | -8.15M | 6.88M | 286.47M | 61.73M | -110.58M |
| Financing Cash Flow | 34.89M | 443.93M | 134.29M | 396.77M | 351.39M |
Ascendis Pharma Technical Analysis
Ascendis Pharma Risk Analysis
Ascendis Pharma Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | $20.38B | 20.28 | 20.04% | ― | 13.50% | 17.16% | |
76 Outperform | $11.72B | 16.08 | 35.53% | ― | 9.93% | 54.33% | |
74 Outperform | $12.03B | 34.48 | 5.94% | ― | 12.31% | 60.21% | |
57 Neutral | $14.42B | -54.32 | ― | ― | 103.32% | 47.55% | |
55 Neutral | $10.09B | -33.82 | -42.49% | ― | 864.21% | 48.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $13.16B | -17.58 | ― | ― | 62.46% | -73.59% |
Ascendis Pharma Corporate Events
Ascendis Pharma reported on February 11, 2026 that fourth-quarter 2025 product revenue reached €240 million and full-year 2025 product revenue €684 million, driven mainly by YORVIPATH, while SKYTROFA contributed €206 million for the year. The company posted a Q4 2025 operating profit of €10 million, generated €73 million in operating cash flow, ended 2025 with €616 million in cash, and plans to start a €120 million share repurchase program in 2026.
Operationally, Ascendis highlighted rapid global uptake of YORVIPATH with more than 5,300 U.S. patient enrollments and availability in over 30 countries, plus commercial launches expected in 10 more markets by year-end 2026. The pipeline advanced with TransCon CNP under FDA priority review with a February 28, 2026 action date, an EMA filing, positive Phase 2 COACH data for TransCon CNP plus TransCon hGH, new Phase 3 and basket trials, and progress in oncology and partnered programs such as a Novo Nordisk obesity collaboration and VISEN’s Chinese approval of TransCon hGH.
These developments position Ascendis for a potential “steep growth phase” as management targets approximately €500 million in operating cash flow in 2026 and aspires to at least €5 billion in annual product revenue by 2030. Growing recurring product sales, broader geographic reach through partners like Teijin and VISEN, and a diversified late-stage pipeline strengthen its standing in the global biopharma market and may enhance value for shareholders and patients in endocrine, metabolic, and oncology indications.
The most recent analyst rating on (ASND) stock is a Buy with a $250.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
On February 10, 2026, Ascendis Pharma’s board granted 16,570 new employee warrants, each giving the right to subscribe for one ordinary share at an exercise price of $224.19, matching the closing price of its American depositary shares on the grant date. The warrants, issued under an appendix to the company’s Articles of Association, vest over four years with 25% vesting after one year and the remainder monthly thereafter, and leave 1,666,633 additional warrants available for future grants, underscoring the company’s continued reliance on equity-based incentives to retain and motivate staff.
In connection with these grants, Ascendis amended its Articles of Association, which also set out broader capital-raising tools including additional warrant programs, share capital increases and convertible bond authorizations. These mechanisms collectively provide the company with flexibility to fund growth, align employee and shareholder interests, and manage its capital structure without necessarily resorting to traditional rights offerings for existing shareholders.
The most recent analyst rating on (ASND) stock is a Buy with a $250.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
On January 13, 2026, Ascendis Pharma’s board of directors granted 42,030 warrants to certain employees, each warrant entitling the holder to subscribe for one ordinary share at an exercise price of $215.05, matching the closing price of the company’s American Depositary Shares on the grant date. The award, which vests over four years subject to continued service and potential accelerated vesting upon specific exit events, required an amendment to the company’s Articles of Association and leaves a further 1,683,203 warrants available for future issuance, signaling continued use of equity-based incentives and potential future dilution for shareholders as part of Ascendis Pharma’s long-term employee retention and alignment strategy.
The most recent analyst rating on (ASND) stock is a Buy with a $250.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
On January 9, 2026, Ascendis Pharma outlined a 2026 business and strategic roadmap highlighting strong commercial uptake of YORVIPATH, which had more than 5,300 unique U.S. patient enrollments and broad international availability by year-end 2025, with further launches planned in at least 10 additional countries by the end of 2026 and continued label-expansion trials. The company noted that SKYTROFA secured its first U.S. label expansion in July 2025 for adult growth hormone deficiency and that a Phase 3 basket trial is underway for additional growth-related indications, while its TransCon CNP program is advancing toward key regulatory decisions in the U.S. and Europe for pediatric achondroplasia and into Phase 3 combination studies with TransCon hGH following positive Phase 2 COACH Trial data reported on January 8, 2026. Ascendis also flagged upcoming 2026 data readouts for its TransCon IL-2 β/γ oncology program, progress of partnered assets with Novo Nordisk in obesity and metabolic disease and with Eyconis in ophthalmology, and regulatory momentum in Greater China and Japan via VISEN Pharmaceuticals and Teijin Limited, including an expected early-2026 approval in China for pediatric growth hormone deficiency and an existing Japanese approval of YORVIPATH in August 2025. In a capital allocation move that may support shareholder value and signal confidence in its outlook, the board authorized a $120 million share repurchase program, giving the company flexibility to buy back stock in the open market or through other permitted methods depending on market conditions and other factors.
The most recent analyst rating on (ASND) stock is a Buy with a $246.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
On January 8, 2026, Ascendis Pharma reported positive Week 52 topline data from its Phase 2 COACH trial, the first study to evaluate once-weekly combination therapy with TransCon CNP and TransCon hGH in children aged 2 to 11 years with achondroplasia, showing durable increases in growth velocity, improved body proportionality and arm span, and no new safety concerns compared with the individual monotherapies. The results, which included annualized growth velocities above the 97th percentile of average-stature children and maintenance of bone age in line with chronological age, support Ascendis’s strategy to advance a Phase 3 program in pediatric achondroplasia and could strengthen the company’s position in the rare endocrine and skeletal dysplasia market as TransCon CNP undergoes priority regulatory review in the U.S. and Europe and all enrolled children continue on treatment in the COACH trial.
The most recent analyst rating on (ASND) stock is a Buy with a $242.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
On December 30, 2025, Ascendis Pharma A/S reported that a scheduled exercise window for its outstanding warrants exercisable into ordinary shares had closed, resulting in a registered increase of its share capital by a nominal DKK 282,197. This brought the company’s total share capital to a nominal DKK 61,977,408 through the issuance of 282,197 new ordinary shares at an average cash consideration of about USD 63.34 per share, strengthening its equity base. In connection with these changes, Ascendis updated and registered amended articles of association with the Danish Business Authority, underscoring the company’s continued use of equity-based incentives and capital market instruments as part of its financing and corporate governance framework.
The most recent analyst rating on (ASND) stock is a Buy with a $250.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
On December 9, 2025, Ascendis Pharma’s board of directors granted 27,820 warrants to certain employees, allowing them to subscribe for ordinary shares at an exercise price of $196.63 per share. This move is part of the company’s strategy to incentivize employees and aligns with its Articles of Association, which were amended to accommodate this grant. The vesting schedule for these warrants includes a 25% vesting after one year and the remainder vesting monthly over the next three years, contingent on continued service. This grant leaves 1,725,233 shares available for future warrants, highlighting Ascendis Pharma’s ongoing commitment to leveraging employee incentives to bolster its market position.
The most recent analyst rating on (ASND) stock is a Buy with a $220.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
On November 25, 2025, Ascendis Pharma announced that the FDA has extended the PDUFA target action date for the New Drug Application of TransCon CNP for children with achondroplasia by three months to February 28, 2026. This extension follows the submission of additional information by Ascendis on November 5, 2025, which the FDA deemed a major amendment. The delay may impact Ascendis’ timeline for bringing this treatment to market, potentially affecting its competitive positioning in the biopharmaceutical industry.
The most recent analyst rating on (ASND) stock is a Buy with a $242.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.